Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat) whose cancer has come back or spread after initial or intensive treatment
• People aged between 18 and 75 years old, of any gender
• People who have a confirmed diagnosis of nasopharyngeal carcinoma through a tissue or cell sample test
• People who are generally well enough to carry out normal daily activities with little or no limitation (confirm with trial site what this level of fitness means for eligibility)
• People who have not previously received any cancer treatment — such as radiation, chemotherapy, immunotherapy, or biological therapy — specifically for the recurrence or spread of their cancer
• People who have no medical reasons preventing them from receiving chemotherapy, immunotherapy, or targeted therapy
• People who have at least one area of cancer that can be measured using standard imaging criteria
• People whose recent blood test results fall within the required ranges for white blood cells, platelets, and haemoglobin, without having needed a blood transfusion or certain blood-boosting medications in the past 14 days
• People whose liver and kidney function blood test results fall within the acceptable ranges set by the trial
• People with healthy blood clotting function, as shown by specific blood test results, or whose clotting results fall within the expected range if they are already taking blood-thinning medication
• People whose heart enzyme levels are within the normal range
• Women who could become pregnant must have had a negative pregnancy test within 7 days of joining and must be willing to use reliable contraception during the trial and for 3 months after the last dose of the study's immune therapy drug; male participants whose partners could become pregnant must also use effective contraception during the trial and for 3 months after the last dose
• People who are willing to participate voluntarily, have signed a consent form, and are able to attend follow-up appointments as required

Who may not be able to join:

• People whose cancer has come back in a localised way that could potentially be treated with surgery or radiation alone
• People who are known to be allergic to the study drug or its ingredients, or who have had a severe allergic reaction to other similar antibody-based medicines
• People who have symptoms of cancer spreading to the brain — such as brain swelling — that require treatment with steroids
• People who have an active infection or an unexplained fever above 38.5°C at the time of screening or before the first dose (though the treating doctor may allow enrolment if the fever is considered to be caused by the tumour itself)
• People who have an active autoimmune disease or a history of autoimmune conditions such as lung inflammation, eye inflammation, bowel inflammation, liver inflammation, or certain thyroid conditions (some exceptions may apply — confirm with trial site); people with vitiligo or childhood asthma that has fully resolved without ongoing treatment may be considered, but people whose asthma requires ongoing medication such as bronchodilators would not be eligible
• People with a known immune deficiency condition such as HIV, or who have active hepatitis B or hepatitis C infection at levels above the trial's specified thresholds
• People who currently have or have previously had another cancer that has not been fully treated and cured, with the exception of certain early-stage or skin cancers that have been successfully treated (such as certain skin cancers, early cervical cancer, or superficial bladder cancer)
• People with serious or poorly controlled heart conditions, including significant heart muscle disease, certain irregular heart rhythms, heart failure of a certain severity, or a heart attack within the past year
• People who have had major surgery and have not fully recovered from its effects before starting treatment
• People who have taken part in another clinical trial within 4 weeks before the first dose of the study drug, or who are currently participating in another clinical study
• People who have received a live vaccine within 4 weeks before the first dose (injected inactivated flu vaccines are permitted, but nasal spray live flu vaccines are not)
• People who are pregnant or breastfeeding
• People who, in the treating doctor's judgement, have other serious medical or personal circumstances — including significant mental health conditions, severely abnormal test results, or family and social factors — that could affect their safety or the reliability of the trial data

Important: Always verify eligibility with the trial site directly before applying.